Swedish biotechnology company Cantargia AB (STO:CANTA) on Friday reported promising new data from the ongoing CAN10 phase 1 clinical study.
All 68 participants receiving a single dose of CAN10 or placebo showed good safety and encouraging biomarker results.
Notably, a single dose of CAN10 has been shown to effectively block IL-1 and IL-36 signalling in the blood for at least one week, achieving key study endpoints. This strengthens the potential of CAN10's unique mechanism of action for treating autoimmune and inflammatory diseases.
The multi-dose portion of the trial is ongoing.
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Frost & Sullivan honours Novotech
Turnstone Biologics announces strategic restructuring
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Novo Holdings launches Booster Therapeutics
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
KeyBioscience extends Eli Lilly collaboration
Tempest to advance amezalpat combination into pivotal trial for HCC
Pharming initiates Phase II clinical trial for leniolisib in PIDs
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Biogen receives FDA Breakthrough Therapy Designation for felzartamab